Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study
Authors:
Open Access
- 30 July 2019
- journal article
- research article
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 17 (3) , 375-386
Abstract
Inhibition of α4β7 integrin has been shown to be effective for induction and maintenance therapy in patients with ulcerative colitis (UC). We investigated the effects of varying doses of the α4β7 inhibitor abrilumab in Japanese patients with moderate-to-severe UC despite conventional treatments. In this randomized, double-blind, placebocontrolled study, 45 UC patients were randomized to abrilumab 21 mg (n=11), 70 mg (n=12), 210 mg (n=9), or placebo (n=13) via subcutaneous (SC) injection for 12 weeks. The double-blind period was followed by a 36-week open-label period, in which all patients received abrilumab 210 mg SC every 12 weeks, and a 28-week safety follow-up period. The primary efficacy variable was clinical remission at week 8 (total Mayo score ≤2 points with no individual subscore >1 point). Clinical remission at week 8 was 4 out of 31 (12.9%) overall in the abrilumab groups versus 0 out of 13 in the placebo group (abrilumab 21 mg, 1/10 [10.0%]; 70 mg, 2/12 [16.7%]; 210 mg, 1/9 [11.1%]). In both the double-blind and open-label periods, fewer patients in the abrilumab groups experienced ≥1 adverse event compared with those in the placebo group. There were no cases of progressive multifocal leukoencephalopathy and no deaths. Abrilumab 70 mg and 210 mg yielded numerically better results in terms of clinical remission rate at Week 8 than placebo, with the 210 mg dose showing more consistent treatment effects. Abrilumab was well tolerated in Japanese patients with UC.Keywords
Funding Information
- AstraZeneca
This publication has 22 references indexed in Scilit:
- Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2015
- Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitisJournal of Gastroenterology, 2013
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2013
- Inflammatory bowel disease in Asia: A systematic reviewJournal of Gastroenterology and Hepatology, 2012
- Epidemiology and Natural History of Inflammatory Bowel DiseasesGastroenterology, 2011
- Prevalence of ulcerative colitis and Crohn’s disease in JapanJournal of Gastroenterology, 2009
- American Gastroenterological Association Institute Medical Position Statement on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel DiseaseGastroenterology, 2006
- Treatment of Ulcerative Colitis with a Humanized Antibody to the α4β7IntegrinNew England Journal of Medicine, 2005
- Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7Gastroenterology, 1996
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987